BCL2 and acute myeloid leukemia: Furthermore, clinical resistance to existing BCL-2 inhibitors like venetoclax has been mechanistically linked to compensatory Mcl-1 upregulation in AML cells (Döhner et al. 2022; Thijssen et al. 2021).